双氢青蒿素纳米结构脂质载体在荷S180瘤小鼠体内的抗肿瘤活性及生物分布研究

doi:10.5246/jcps.2013.04.050

双氢青蒿素纳米结构脂质载体在荷S180瘤小鼠体内的抗肿瘤活性及生物分布研究

张晓云^*, 乔华, 赵鹏, 倪京满, 史彦斌

1. 兰州大学药学院, 甘肃兰州 730000
2. 兰州大学第一医院药剂科, 甘肃兰州 730000
3. 兰州大学第一医院肿瘤科, 甘肃兰州 730000

收稿日期:2012-09-21 修回日期:2012-11-19 出版日期:2013-07-10 发布日期:2013-07-10
通讯作者: 张晓云*

Antitumor activity and biodistribution of DHA-NLC formulation in sarcoma 180-bearing mice

Xiaoyun Zhang^*, Hua Qiao, Peng Zhao, Jingman Ni, Yanbin Shi

1. School of Pharmacy, Lanzhou University, Gansu 730000, China
2. Department of Pharmaceutics, the First Hospital of Lanzhou University, Gansu 730000, China
3. Department of Oncology, the First Hospital of Lanzhou University, Gansu 730000, China

Received:2012-09-21 Revised:2012-11-19 Online:2013-07-10 Published:2013-07-10
Contact: Xiaoyun Zhang*

摘要/Abstract

摘要：

近年来脂质纳米粒由于其优越的特征备受青睐。本文通过腹腔注射评价了双氢青蒿素纳米结构脂质载体在荷S180瘤小鼠体内的抗肿瘤作用, 以及在荷S180昆明鼠内的生物分布研究。结果表明双氢青蒿素纳米结构脂质载体显著抑制了肿瘤的增长, 通过腹腔给药在20, 40和80 mg/kg时肿瘤抑制率分别为71.24%, 79.20%和85.74%, 在荷S180小鼠体内静脉注射双氢青蒿素纳米结构脂质载体后, 药物的生物分布表明双氢青蒿素纳米结构脂质载体与双氢青蒿素溶液相比, 双氢青蒿素纳米结构脂质载体显示了明显不同的生物分布。因此, 本文实验结果确实证明了双氢青蒿素纳米结构脂质载体与双氢青蒿素普通混悬液相比, 在相同剂量下双氢青蒿素纳米结构脂质载体显示出更优越的抗肿瘤作用和剂量依赖性。

关键词: 纳米结构脂质载体, 抗肿瘤, S180, 生物分布

Abstract:

Lipid nanoparticles have become attractive for its prominent properties recent years. In this paper, in vivo anti-tumor efficacy of nanostructured lipid carrier of dihydroartemisinin (DHA-NLC) were evaluated in sarcoma 180-bearing mice model through intraperitoneal (i.p.) administration. In vivo biodistribution was also investigated in Kunming mice bearing S180. Results demonstrated that the intraperitoneally injected DHA-NLC could significantly inhibit tumor growth at the dose levels of 20, 40 and 80 mg/kg, and their inhibition rates were 71.24%, 79.20% and 85.74%, respectively. The biodistribution of DHA after intraperitoneal injection of DHA-NLC in S180-bearing mice is remarkably different from the DHA solution. Therefore, DHA encapsulated in NLC does demonstrate superior anticancer effect to DHA suspension on S180-bearing mice at the same dose and displayed a dose-dependent antitumor efficacy.

Key words: Nanostructured lipid carrier, Antitumor, Sarcoma 180, Biodistribution

中图分类号:

Supporting:

Foundation items: Fundamental Research Funds of Lanzhou University for the Central Universities (Grant No. lzujbky-2012-85) and the Lanzhou Science and Technology Bureau (Grant No. 2012-2-80).
^*Corresponding author. Tel./Fax: 86-931-8915686

张晓云^*, 乔华, 赵鹏, 倪京满, 史彦斌. 双氢青蒿素纳米结构脂质载体在荷S180瘤小鼠体内的抗肿瘤活性及生物分布研究[J]. , DOI: 10.5246/jcps.2013.04.050.

Xiaoyun Zhang^*, Hua Qiao, Peng Zhao, Jingman Ni, Yanbin Shi. Antitumor activity and biodistribution of DHA-NLC formulation in sarcoma 180-bearing mice[J]. , DOI: 10.5246/jcps.2013.04.050.

参考文献

[1] Smets, A. Anti-cancer Drug. 1994, 5, 3-9.
[2] Langer, R. Accounts Chem Res. 2000, 33, 94-101.
[3] Van Vlerken, L.E.; Duan, Z.; Little, S.R.; Seiden, M.V.; Amiji, M.M. Mol. Pharm. 2008, 5, 516-526.
[4] Müller, R.H.; Radtke, M.; Wissing, S.A. Adv. Drug Deliv. Rev. 2002, 54, 131-155.
[5] Müller, R.H.; Keck, C.M. J. Biotechnol. 2004, 113, 151-170.
[6] Alvarez-Román, R.; Naik, A.; Kalia, Y.N.; Guy, R.H.; Fessi, H. J. Control. Release. 2004, 99, 53-62.
[7] Monika, S.K.; Wolfgang, M.; Hans-Christian, K. Adv. Drug Deliv. Rev. 2007, 59, 427-443.
[8] Paolo, B.; Stefano, G.; Aurélie, S.; Maurizio, R.; Carlo, R. Adv. Drug Deliv. Rev. 2007, 59, 454-477.
[9] Lin, X.H.; Li, X.W; Zheng, L.Q.; Yu, L.; Zhang, Q.Q.; Liu, W.C. Colloid Surf. A. Physicochem. Eng. Asp. 2007, 311, 106-111.
[10] Maeda, H.; Wu, J.; Sawa, T.; Matsumura,Y.; Hori, K. J. Control. Release. 2000, 65, 271-284.
[11] O'Neill, P.M. Nature. 2004, 430, 838-839.
[12] O'Neill, P.M.; Posner, G.H. J. Med. Chem. 2004, 47, 2945-2964.
[13] White, N.J. J. Clin. Invest. 2004, 113, 1084-1092.
[14] Monica, L.; Sara, Z.; Debora, M.; Marco, B.; Paolo, C.; Jacqueline, L.; Guy, M.; Melba, G.; Walter, R.J.; Taylor, P.O. Reprod. Toxicol. 2006, 21, 83-93.
[15] Wu, G.D.; Zhou, H.J.; Wu, X.H. Vascul. Pharmacol. 2005, 41, 205-212.
[16] Jacob, G.; Judith, H.W.; Miriam, K.; Nicholas, H.H.; Georges, E.G. Int. J. Parasitol. 2006, 36, 1427-1441.
[17] Ikuhiko, N.; Henry, L.; Narendra, P.; Singh, T.S. Int. J. Pharm. 2008, 354, 28-33.
[18] Zhang, X.Y.; Liu, J.P.; Qiao, H.; Liu, H.; Ni, J.M.; Zhang, W.L.; Shi, Y.B. Powder Technol. 2010, 197, 120-128.
[19] Zhang, X.Y.; Qiao, H.; Liu, J.P.; Dong, H.J.; Shen, C.L.; Ni, J.M.; Shi, Y.B; Xu, Y. Pharmazie. 2010, 65, 670-678.
[20] Bezerra, D.P.; Castro, F.O.; Alves, A.P.; Pessoa, C.; Moraes, M.O.; Silveira, E.R.; Lima, M.A.; Elmiro, F.J.; Alencar, N.M.; Mesquita, R.O.; Lima, M.W.; Costa-Lotufo, L.V. J. Appl. Toxicol. 2008, 28, 156-163.
[21] Zheng, M.L.; Han, B.Q.; Yang, Y.; Liu, W.S. Carbohydr. Polym. 2011, 86, 231-238.
[22] Wei, Y.Q.; Huang, M.J.; Yang, L.; Zhao, X.; Tian, L.; Lu, Y.; Shu, J.M.; Lu, C.J.; Niu, T.; Kang, B.; Mao,Y.Q.; Liu, F.; Wen, Y.J.; Lei, S.; Luo, F.; Zhou, L.Q.; Peng, F.; Jiang, Y.; Liu, J.Y.; Zhou, H.; Wang, Q.R.; He, Q.M.; Xiao, F.; Lou, Y.Y.; Xie, X.J.; Li, Q.; Wu, Y.; Ding, Z.Y.; Hu, B.; Hu, M.; Zhang, W. Proc. Natl. Acad. Sci. USA. 2001, 98, 11545-11550.
[23] Wang, J.; Chen, C.; Li, B.; Yu, H.; Zhao, Y.; Sun, J.; Li, Y.; Xing, G.; Yuan, H.; Tang, J.; Chen, Z.; Meng, H.; Gao, Y.; Ye, C.; Chai, Z.; Zhu, C.; Ma, B.; Fang, X.; Wan, L. Biochem. Pharmacol. 2006, 71, 872-881.
[24] Zhang, L.Y.; Yang, M.; Wang, Q.; Li, Y.; Guo, R.; Jiang, X.Q.; Yang, C.Z.; Liu, B.R. J. Control. Release. 2007, 119, 153-162.
[25] Morille, M.; Montier, T.; Legras, P.; Carmoy, N.; Brodin, P.; Pitard, B.; Benoit, J.P.; Passirani, C. Biomaterials. 2010, 31, 321-329.
[26] Moghimi, S.M.; Hunter, A.C.; Murray, J.C. Pharmacol. Rev. 2001, 53, 283-318.
[27] Brigger, I.; Couvreur, P. Adv. Drug Deliv. Rev. 2002, 54, 631-651.
[28] Iodoshima, N.; Udagawa, C.; Ando, T.; Fukuyasu, H.; Watanabe, H.; Nakabayashi, S. Int. J. Pharm. 1997, 146, 81-92.
[29] Koshkina, N.; Waldrep, J.; Knight, V. Curr. Cancer Drug Targets. 2003, 3, 251-264.
[30] Chiannilkulchai, N.; Ammoury, N.; Caillou, B.; Devissaguet, J.; Couvreur, P. Cancer Chemother. Pharmacol. 1990, 26, 122-126.
[31] Soma, C.E.; Dubernet, C.; Barratt, G.; Benita, S.; Couvreur, P. J. Control. Release. 2000, 68, 283-289.
[32] Mehnert, W.; Mader, K. Adv. Drug Deliv. Rev. 2001, 47, 165-196.
[33] Gabriëls, M.; Plaizier, V.J. Int. J. Pharm. 2004, 274, 245-260.
[34] Batty, K.T.; Davis, T.M.E.; Thu, L.T.A.; Binh, T.Q.; Anh, T.K.; Ilett, K.F. J. Chromatogr. B. 1996, 677, 345-350.